. Primary endpoints included knowledge of HPV and its causal relationship to penile cancer. Baseline characteristics included sex, age, education, race & ethnicity, income, residency, personal or family history of cancer, health insurance status, and internet use. Multivariable logistic regression assessed predictors of HPV and penile cancer knowledge.
INTRODUCTION AND OBJECTIVES:
The International Metastatic Renal Cell Carcinoma Database (IMDC) Criteria (Heng Criteria) is a validated risk prediction tool for patients with metastatic renal cell carcinoma (mRCC). It provides valuable prognostic data but clinical application can be challenging due to limited available tools. We created an interactive visualization to facilitate clinical application of IMDC Criteria.
METHODS: A multi-institutional cohort of 436 patients with mRCC was used to create an interactive visualization depicting IMDC Criteria at the patient level. Usability testing was performed with nonmedical lay-users and medical oncology fellows. Subjects used the tool to calculate median survival times based on IMDC Criteria in six increasingly complex clinical scenarios. Confidence using the tool was surveyed and measured along a 5-point Likert scale.
RESULTS: The interactive visualization is available at http:// www.cloviz.org. 400 lay-users and 15 medical oncology fellows completed clinical scenarios and surveys. Overall, lay-users were able to obtain the exact correct answer in 48% of scenarios, compared to 60% of medical oncology fellows. The proportion of exact correct answers decreased with increasing task complexity, but the proportion of answers within 25% of the expected answer remained stable at 68-78% for layusers and 73-93% for medical oncology fellows. When surveying usability, 65% of lay-users felt it was easy to use, compared to 80% of fellows, and 83%-87% felt it became intuitive with increasing use, respectively. Among lay-users, 69-77% were confident selecting lab values and drug names, compared to 87-93% of medical oncology fellows. 75% of lay-users felt it helped them better understand survival in mRCC. 68% of lay-users wanted to use a similar tool with their doctor, while 87% of medical oncologists wanted to use this with patients and 93% wanted to incorporate it into their clinical practice in some way.
CONCLUSIONS: A graphical method of interacting with a validated nomogram for mRCC outcomes provides real-time individual level data that can be used by untrained nonmedical users and medical oncologists, with potential for use in the clinic setting. Decisional quality is a multidimensional construct that can be used to measure the impact of the decision making process. Decisional quality has been defined to include decisional conflict, disease specific knowledge, patient satisfaction, and sense that SDM has occurred in the visit. For patients that have urologic stone disease, little is known about decisional quality and shared decision making. METHODS: We identified new patients scheduled for evaluation of kidney stones within a large academic clinical setting. After the initial consultation, we conducted a patient feedback telephone survey. The survey instrument included the 4-item SURE instrument to evaluate decisional quality, 3 related items which measured specific concepts related to decisional conflict, 10 items measuring disease-specific knowledge, 1 item addressing patient satisfaction, the Net Promoter Score survey to measure patient loyalty, three items from the Shared Decision Making Questionnaire (SDM-Q), and a single question querying health literacy. We also evaluated their treatment preferences before and after the consultation.
RESULTS: A total of 29 out of 30 patients we contacted participated in the survey. Fourteen patients had perfect SURE scores (SURE¼4), indicating no decisional conflict, while 15 patients had scores indicating high decisional conflict after seeing the counseling urologist. Patients with perfect SURE scores reported improved perceived interactions with their urologist, feeling more included in the Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e121 treatment decision (p ¼ 0.0063), and were more likely to discuss treatment options (p ¼ 0.0052). The total SDM scores indicated that patients without evidence of decisional conflict reported more perceived shared decision making (p ¼ 0.0009). These patients also had higher Net Promoter Scores (higher intended physician loyalty) (p ¼ 0.0086).
There was no significant difference between the two groups in health literacy scores or disease specific knowledge scores. CONCLUSIONS: This cross-sectional analysis of patients with nephrolithiasis suggests that lower decisional conflict after a urologic consultation for nephrolithiasis is associated with more shared decisionmaking and with higher levels of patient loyalty after consultation. Our data identifies specific areas that can be targeted with pre-consultation interventions aimed at building a solid foundation of shared decision making with the intent of improving decisional quality. METHODS: Men were randomized to P3P+UC or UC alone after responding to a baseline query of influential personal factors. The P3P, a tailored educational/coaching tool, was provided prior to the options review consult at 7 practices across the US. The low literacy DC scale (DCS) was administered at baseline and 1 month. One-month DCS (total score (TS) and 4 subscales) was compared by group using ANCOVA. Factors previously identified as influencing DC (age, education, partner status, working status, income, race, D 0 Amico risk levels, information resources, baseline/one-month decisional status, baseline DCS and study site) were assessed univariately and then adjusted in multivariable analysis. Backwards model selection was used and two-way interactions checked. RESULTS: 392 (198 P3P, 194 UC) men were randomized. 309 (155 P3P, 154 UC) men returned 1 month DCS. No significant study group effect was indicated for the TS or subscales univariately. In multivariable analyses, P3P marginally reduced TS conflict (LSmean¼3.19, P¼0.06) and significantly reduced conflict related to being informed (LSmean ¼6.99, P¼0.0004). There were significant group interactions with partner status for the TS and income for the informed subscale. Unpartnered P3P users had significantly lower total conflict compared to partnered men in both groups (P¼0.0005) and UC unpartnered men (p¼0.03). Among low income men, UC had significantly higher conflict on the informed subscale compared to P3P users (P<0.0001) and higher income men in both groups (P<0.0001). Overall, partnered and/or low income men had higher conflict in TS, as well as in 3 subscales. Men undecided at 1-mo had significantly higher conflict in TS and all subscales. Study site significantly impacted the TS, informed and value clarity subscales. Men who were working or used the Internet for information had significantly lower conflict in the value clarity subscale. Low D 0 Amico risk level was significantly associated with higher uncertainty.
Source of
CONCLUSIONS: The P3P is superior to UC with regard to informing men about LPC options. Our results have implications for who is at risk for greater DC. Men with lowest risk disease, and likely more options, are more uncertain. Men with partners/spouses and low income men are more likely to be conflicted. Decision support for partners is an important next step. , a process in which clinicians and patients collaborate to make decisions that are well informed and consistent with patients 0 preferences and values, helps guide patients through this decision making process and improves patient satisfaction. The objective of this study was to evaluate the feasibility and initial outcomes of measuring SDM among men with newly diagnosed localized prostate cancer, and to assess patients 0 perceptions of the value of existing decision support resources. METHODS: Over a one year period, all men with newly diagnosed localized prostate cancer were enrolled prospectively in this pilot study at an academic tertiary care center. All men were referred for nurse navigation, were offered referral to urology and radiation oncology, and were provided access to a prostate cancer educational website. At the time of informed consent for their chosen managment option (surveillance, surgery, radiation), men were invited to complete CollaboRATE, a validated 3-question survey measuring perceptions of SDM, along with measures assessing the perceived value of available decision support resources. Descriptive and correlational analyses were conducted to examine the prevalence of SDM and its associations with the perceived value of decision support resources.
RESULTS: Annualized volume of prostate cancer diagnosis within our medical center was 249 per year, and 132 patients (53%) completed CollaboRATE. Descriptive frequencies of perceived value and CollaboRATE scores are reported in Table 1 . Correlations between CollaboRATE and perceived value scores were non-significant.
CONCLUSIONS: Routine measurement of SDM and patient perceptions of the value of decision support resources is feasible but challenging, and though the prevalence of SDM was high it was not optimal. Physicians represent the most highly valued decision support resource. Measuring SDM and the value of decision support services from the patient perspective provides useful information to improve the quality of care for patients with newly diagnosed localized prostate cancer.
